Form D · Biotechnology

NORMOXYS, INC.

Boston, MA · CIK 0001411024

Offering snapshot reported Nov 21, 2011 · SEC filing

Reported sold
$600K
Offering amount: $1.1M
Investors reported
6
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 7, 2011
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 21, 2011Initial$600,000No comparison6SEC filing
Jun 23, 2011Initial$1,556,353No comparison13SEC filing
May 25, 2010Initial$17,564,384No comparison15SEC filing
Mar 24, 2010Initial$1,050,000No comparison7SEC filing
Apr 29, 2009Initial$4,506,708No comparisonNot reportedSEC filing
Aug 27, 2007PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Debt, Other
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-169004
Secured Convertible Promissory Notes

Source: Form D, filed Nov 21, 2011. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Conrad Bletzer, Jr. Executive
David Clark Executive
Francesco De Rubertis Director
Dr. Jean Pierre Garnier Director
Jean Pierre Garnier Director
Argeris Karabelas Director
Jean Marie Lehn Director
Sara Mckenzie Executive
Claude Nicolau Director
Michele Ollier Director
Martin Tolar Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
300 Market Street
Boston, MA, 02135